Neoplasms, Second Primary  >>  iniparib (BSI 201)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
iniparib (BSI 201) / Sanofi
NCT01173497: A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark Data
May 2011 - May 2011: Data
Completed
2
44
US
INIPARIB + irinotecan
Sanofi, UNC Lineberger Comprehensive Cancer Center
Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
10/12
07/13

Download Options